Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Hormonal and physiological effects of a 15 hour road journey in sheep: comparison with the responses to loading, handling and penning in the absence of transport

A controlled study was carried out to investigate the physiological effects of road transport on sheep. Animals (n=10, body weight 38.9+/-1.3 kg), previously with catheters in their jugular veins, were rounded up and loaded onto a vehicle where they wereheld in a communal pen with eight other lambs. Blood samples were taken at 30 min intervals during the next 15 h whilethe vehicle remained stationary or was driven a distance of 548 miles (876 km). Measurements were made of plasma concentrations of cortisol, prolactin, creatine phosphokinase and lactate dehydrogenase isozymes and also of plasma osmolality, haematocrit and body weight; heart rate was also recorded in one animal. Loading and the start of driving produced large increases in cortisol and prolactin concentrations. Heart rate also increased whereas osmolality and haematocrit decreased. The major changes in hormone release occurred in the first 3 h period while, during the remaining 12 h, the stimulatory effect of transport was present but small. Body weight loss was similar under both stationary and driven conditions

Structural evolution of tetraphenylethene with temperature observed using THz-TDS

Structural evolution with temperature of tetraphenylethene (TPE) is followed using THz-TDS. The observed changes in the terahertz spectra are rationalized by performing DFT calculations on experimentally determined low and high temperature crystal structures, thus allowing the changes to be rationalized in terms of the subtle changes in the supramolecular structure. © 2013 IEEE

Active coke Carbonaceous materials as catalysts for alkane dehydrogenation

The catalytic dehydrogenation (DH) and oxidative dehydrogenation (ODH) of light alkanes are of significant industrial importance. In this work both carbonaceous materials deposited on VOx/Al2O3 catalysts during reaction and unsupported carbon nanofibres (CNFs) are shown to be active for the dehydrogenation of butane in the absence of gas-phase oxygen. Their activity in these reactions is shown to be dependent upon their structure, with different reaction temperatures yielding structurally different coke deposits. Terahertz time-domain spectroscopy (THz-TDS), among other techniques, has been applied to the characterisation of these deposits – the first time this technique has been employed in coke studies. TEM and other techniques show that coke encapsulates the catalyst, preventing access to VOx sites, without a loss of activity. Studies on CNFs confirm that carbonaceous materials act as catalysts in this reaction. Carbon-based catalysts represent an important new class of potential catalysts for DH and ODH reactions